Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease–associated Colorectal Dysplasia and Adenocarcinoma. (October 2019)

• Record Type: Journal Article
• Authors: Ma, Changqing; Henn, Patrick; Miller, Caitlyn; Herbst, Cameron; Hartman, Douglas J.; Pai, Reetesh K.
• Is Part Of: American journal of surgical pathology. Volume 43:Number 10(2019)
• Publication Date: 2019-10
• Subjects: SATB2 -- CDX2 -- immunohistochemistry -- ulcerative colitis -- Crohn disease -- dysplasia -- neoplasia, colorectal carcinoma -- prognosis -- survival; Pathology, Surgical -- Periodicals; 617.0705
• DOI: 10.1097/PAS.0000000000001330
• Languages: English
• ISSNs: 0147-5185

Abstract

Abstract : SATB2 is a sensitive immunohistochemistry marker of colorectal carcinoma and non-neoplastic colorectal epithelium that is complementary to CDX2. However, its expression is affected by molecular alterations. Inflammatory bowel disease–associated neoplasia demonstrates molecular alterations that are different from those in sporadic colorectal neoplasia. Given these differences, we examined SATB2 expression in 73 cases of inflammatory bowel disease–associated neoplasia including 37 dysplasia cases and 36 carcinomas and compared the expression patterns with 50 cases of nondysplastic colorectal mucosa in patients with active inflammatory bowel disease, 40 sporadic colonic polyps (20 conventional adenomas and 20 sessile serrated lesions/polyps), and 343 sporadic colorectal adenocarcinomas to assess SATB2 immunohistochemistry as a biomarker of inflammatory bowel disease–associated neoplasia. Loss of SATB2 expression was only identified in colorectal dysplasia arising in inflammatory bowel disease (15/37, 41%) and was not seen in nondysplastic colorectal mucosa with active inflammatory bowel disease or sporadic colonic polyps ( P <0.001). Loss of SATB2 expression was identified in both endoscopically visible dysplasia (11/28, 39%) and invisible (4/9, 44%) dysplasia. Loss of SATB2 expression was identified in 67% (24/36) of inflammatory bowel disease–associated carcinomas and was significantly more frequent compared with sporadic colorectal carcinomas (47/343, 14%, P <0.001). There was no difference in positive CDX2 expression between inflammatory bowel disease–associated colorectal carcinoma and sporadic colorectal carcinoma (89% vs. 85%, P =1.0). In conclusion, loss of SATB2 expression is common in inflammatory bowel disease–associated colorectal dysplasia and adenocarcinoma and may be a helpful ancillary biomarker when evaluating for inflammatory bowel disease–associated dysplasia. Abstract : Supplemental Digital Content is available in the text.